ArticlePloS one2026
RUBCN as a novel prognostic biomarker and therapeutic target in breast cancer.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Analysis of autophagy-related gene expression data identified RUBCN as a novel biomarker influencing the pathogenesis and progression of breast cancer, underscoring its potential as a therapeutic target. We analyzed multiple breast cancer sample datasets using bioinformatics tools and databases. A consensus prognostic model was constructed and validated across several independent datasets to further examine its association with patient outcomes. A series of bioinformatics analyses focused on RUBCN were conducted, including expression profiling, independent prognostic evaluation, immune correlation analysis, and survival analysis. RUBCN expression was verified in breast cancer cell lines and clinical tissue specimens via Western blotting, quantitative real-time reverse transcription PCR, and immunohistochemistry. Functional assays, such as the Cell Counting Kit-8 assay, 5-ethynyl-2'-deoxyuridine incorporation assay, wound healing assay, and Transwell invasion assay, were employed to evaluate the effects of RUBCN knockdown on breast cancer cell proliferation and invasion. Autophagic activity, indicated by LC3 and P62 levels, was measured via Western blot in RUBCN-knockdown breast cancer cells with or without chloroquine treatment. Elevated expression of multiple autophagy-related genes was observed in breast cancer. The consensus prognostic model accurately predicted survival across multiple datasets, with RUBCN emerging as a key gene whose expression levels were significantly correlated with patient prognosis. Enrichment analysis indicated that RUBCN likely promotes breast cancer progression by regulating cell cycle and invasion processes. Further investigation revealed a negative correlation between RUBCN expression levels and immune cell infiltration, suggesting a potential role in mammary tumorigenesis through mediating immune evasion by suppressing immune cell infiltration. Immunohistochemical results confirmed upregulated RUBCN expression in carcinoma tissues. Knockdown of RUBCN was shown to suppress the proliferative and invasive abilities of breast cancer cells. Mechanistically, RUBCN knockdown impaired autophagic flux, as evidenced by altered LC3 and P62 levels upon chloroquine treatment. Together, these findings establish RUBCN as a promising therapeutic target in breast cancer. Future studies should emphasize in vivo functional validation using animal models and screen for targeted agents capable of modulating RUBCN expression or activity, thereby facilitating the development of innovative therapeutic strategies for breast cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.